Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H9X-MC-GBDG dulaglutide vs placebo in type 2 diabetes on sulfonylurea
2012-002911-24Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dulaglutide 1.5 mg once weekly with Placebo once weekly (2 arms). Primary endpoint: Change in HbA1c from baseline to 24 weeks. Started Dec 2012; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-002911-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002911-24.